ClinicalTrials.gg
CompletedNCT07937644PHARM-MDDUpdated Nov 16, 2026

Effect of Clinical Pharmacist-Led Pharmaceutical Care in Major Depressive Disorder

An interventional study of Clinical Pharmacist-Led Pharmaceutical Care in Major Depressive Disorder (MDD) and Medication Adherence, sponsored by Marmara University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Marmara University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 10 months after the study started (first participant enrolled Dec 2024, registered Nov 2026).
Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
186
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 32 studies in Depressive Disorder, Major with a site in Turkey — 14 open to participants now, 15 under way, 1 of them phase 3. Depressive Disorder, Major · Turkey.

Enrollment
9th of 24
186 · median 95
Started
2024
with 6 others
No phase
11 of 32
6 open now
Registered
32nd of 32
by date

Among the 32 studies in Depressive Disorder, Major with a site in Turkey, this one is the 9th largest by enrollment of the 24 interventional ones that give a count, is one of 7 that started in 2024, is one of 11 with no phase, and was the 32nd registered.

Depressive Disorder, Major

3,050 studies on the registry are indexed under Depressive Disorder, Major; 594 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

14 of the 32 studies in Depressive Disorder, Major with a site in Turkey are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 415 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 295 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Depressive Disorder, Major with a site in Turkey, or all of them as a file.
02

Study summary

This randomized controlled trial evaluated the effects of a six-month clinical pharmacist-led pharmaceutical care intervention on medication adherence, beliefs about medicines, and health-related quality of life in adults diagnosed with major depressive disorder (MDD) receiving antidepressant treatment.

A total of 186 participants were randomized in a 1:1 ratio to receive either structured pharmaceutical care in addition to usual psychiatric care or usual psychiatric care alone. Of these, 170 participants completed the six-month follow-up.

The intervention included individualized patient counseling, medication review, identification and management of medication-related problems, and telephone follow-up every two weeks.

Medication adherence was assessed using the Medication Adherence Report Scale (MARS-5), beliefs about medicines using the Turkish Beliefs about Medicines Questionnaire (BMQ-T), and health-related quality of life using the EQ-5D-3L and EQ-VAS. Assessments were conducted at baseline, Month 3, and Month 6.

Read the detailed description

This prospective, single-center, open-label, parallel-group randomized controlled trial was conducted at a psychiatry outpatient clinic affiliated with Marmara University in Istanbul, Türkiye. Eligible adults were 18-65 years old, met DSM-IV or DSM-5 criteria for major depressive disorder, and had received antidepressant medication for at least one month. Participants were allocated in a 1:1 ratio using a computer-generated simple randomization sequence. According to the manuscript, allocation was performed by an independent administrative staff member not involved in enrollment, intervention, follow-up, or outcome assessment, and the allocation sequence was concealed from the recruiting investigator until eligibility and enrollment were completed. The intervention group received individualized clinical pharmacist-led pharmaceutical care in addition to usual psychiatric care. The care included education and counseling, medication history review, assessment of medication-related problems and adverse effects, identification of adherence barriers, an individualized care plan, collaboration with the treating psychiatrist as needed, and contact by telephone or message every 15 days for six months. The control group received usual psychiatrist-led care without the structured pharmacist intervention during follow-up. Outcome assessments occurred at baseline, Month 3, and Month 6. A total of 186 participants were randomized (93 per group), and 170 completed six-month follow-up (84 intervention; 86 control).

03

Conditions studied

  • Major Depressive Disorder (MDD)
  • Medication Adherence

Keywords

  • Pharmaceutical Care
  • Medication Adherence
  • Antidepressants
  • Beliefs about medicines
  • Health-Related Quality of Life
  • Clinical Pharmacist
  • Patient Education
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18-65 years.
  • Diagnosis of major depressive disorder (MDD) by a psychiatrist according to criteria.
  • Receiving maintenance antidepressant treatment for at least one month.
  • Ability to communicate effectively in Turkish.
  • Willingness to participate in the study and provision of written .
  • Availability to complete the scheduled follow-up assessments.

Exclusion criteria

Exclusion Criteria:

  • History of bipolar disorder, psychotic disorders, or other severe psychiatric disorders that could interfere with study participation.
  • Drug or substance dependence.
  • Pregnancy.
  • Active cancer.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
186 participants (actual)

Study arms

  • Experimental
    Clinical Pharmacist-Led Pharmaceutical Care

    Participants assigned to this group received structured clinical pharmacist-led pharmaceutical care in addition to usual psychiatric care for six months. The intervention included individualized patient education and counseling, medication review, identification and management of medication-related problems, monitoring of adverse effects, and telephone follow-up every two weeks.

    Other: Clinical Pharmacist-Led Pharmaceutical Care

  • No intervention
    Usual Psychiatric Care

    Participants assigned to the control group received usual psychiatric care, including routine clinical follow-up and antidepressant treatment as prescribed by their treating psychiatrist. No additional structured clinical pharmacist-led pharmaceutical care intervention was provided during the six-month study period. Outcome assessments were conducted at baseline, Month 3, and Month 6.

Interventions

  • OtherClinical Pharmacist-Led Pharmaceutical Care

    A structured six-month clinical pharmacist-led pharmaceutical care intervention consisting of individualized patient counseling, medication review, identification and management of medication-related problems, monitoring of adverse effects, and telephone follow-up every two weeks, provided in addition to usual psychiatric care.

06

What researchers measure

Primary outcomes

  1. Change in Medication Adherence as Measured by MARS-5

    Medication adherence was assessed using the five-item Medication Adherence Report Scale (MARS-5). Each item is scored from 1 to 5, yielding a total score ranging from 5 to 25. Higher scores indicate better medication adherence. Changes in total MARS-5 scores were assessed at baseline, Month 3, and Month 6 to evaluate the effectiveness of the clinical pharmacist-led pharmaceutical care intervention.

    Time frame: Baseline, Month 3, and Month 6

Secondary outcomes

  1. Change in Beliefs About Medicines - Specific Necessity

    Beliefs about the necessity of prescribed antidepressant medication were assessed using the Specific Necessity subscale of the Turkish Beliefs about Medicines Questionnaire (BMQ-T). Scores range from 5 to 25, with higher scores indicating stronger perceived necessity of medication.

    Time frame: Baseline, Month 3, and Month 6

  2. Change in Beliefs About Medicines - Specific Concerns

    Concerns about prescribed antidepressant medication were assessed using the Specific Concerns subscale of the Turkish Beliefs about Medicines Questionnaire (BMQ-T). Scores range from 5 to 25, with higher scores indicating greater concerns about medication use.

    Time frame: Baseline, Month 3, and Month 6

  3. Change in Beliefs About Medicines - General Overuse

    General beliefs regarding the overuse of medicines by physicians were assessed using the General Overuse subscale of the Turkish Beliefs about Medicines Questionnaire (BMQ-T). Scores range from 4 to 20, with higher scores indicating stronger beliefs that medicines are overprescribed.

    Time frame: Baseline, Month 3, and Month 6

  4. Change in Beliefs About Medicines - General Harm

    General beliefs about the harmful effects of medicines were assessed using the General Harm subscale of the Turkish Beliefs about Medicines Questionnaire (BMQ-T). Scores range from 4 to 20, with higher scores indicating stronger beliefs that medicines are harmful.

    Time frame: Baseline, Month 3, and Month 6

  5. Change in Health-Related Quality of Life (EQ-5D-3L Index)

    Health-related quality of life was assessed using the EuroQol 5-Dimension 3-Level questionnaire (EQ-5D-3L). Responses across five dimensions were converted into a health utility index using a value set. Higher index values indicate better health-related quality of life.

    Time frame: Baseline, Month 3, and Month 6

  6. Change in Self-Rated Health Status (EQ-VAS)

    Self-rated health status was assessed using the EuroQol Visual Analogue Scale (EQ-VAS), ranging from 0 (the worst imaginable health) to 100 (the best imaginable health). Higher scores indicate better self-perceived health status.

    Time frame: Baseline, Month 3, and Month 6

07

Study locations

1 site
  • Marmara University Pendik Training and Research Hospital
    Istanbul, Turkey (Türkiye)
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2024 to primary completion in Mar 2026, 15 months.

Of 653 non-industry interventional studies with no phase under Depressive Disorder, Major, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 55. This study's 15 months is below that.

Counting every sponsor, half of 693 studies reached it within 33 months; a quarter within 17 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2026
First posted
Nov 16, 2026
StartActual
Dec 25, 2024
Primary completionActual
Mar 30, 2026
CompletionActual
Jun 30, 2026
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07937644
Lead sponsor
Marmara University
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Dec 25, 2024
Primary completion
Mar 30, 2026
Completion
Jun 30, 2026
Last update
Nov 16, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion